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Insulin release from pancreatic islets: Effects of CRF and excess PTH.
Insulin secretion may be impaired in chronic renal failure (CRF) and
available data suggest that this abnormality may be related to the state
of secondary hyperparathyroidism of renal failure. We directly mea-
sured insulin release from isolated islets of Langerhans obtained from
normal rats, CRF-control and CRF-PTX (parathyroidectomized) rats,
and parathyroid hormone (PTH)-treated animals. Both early and total
glucose-induced insulin release from islets of CRF-control were mark-
edly and significantly (P < 0.01) lower than from islets of normal rats.
Insulin release from islets of CRF-PTX rats was significantly (P <0.01)
higher than that from islets of CRF-control rats, and not different from
insulin release from islets of normal rats. Forskolin and IBMX, which
cause a rise in cAMP, significantly stimulated glucose-induced insulin
release from islets of normal, CRF-control and CRF-PTX rats, but the
increments from baseline were not significantly different between the
three groups. Both early and total insulin release from islets obtained
from PTH-treated rats with normal renal function were markedly and
significantly (P < 0.01) lower than values obtained from normal rats.
Calcium contents of the pancreas of CRF-control and PTH-treated rats
were significantly (P < 0.01) higher than that in pancreas of normal rats
and CRF-PTX animals, and values in the latter two groups of animals
were not significantly different. The results show that: I) CRF impairs
insulin release from pancreatic islets; 2) this abnormality is reversed by
prior parathyroidectomy; and 3) hyperparathyroidism induced by PTH-
treatment in normal rats impairs insulin release from pancreatic islets.
The data provide a direct evidence for the role of secondary hyperpara-
thyroidism in the genesis of abnormal carbohydrate metabolism in
CRF. This effect of excess PTH is not related to alterations in cAMP
production but may potentially be due to calcium accumulation in the
pancreas.
Available data in dogs [1] indicate that glucose intolerance
does not develop in chronic renal failure (CRF) in the absence
of parathyroid hormone (PTH). Also studies in uremic or
dialyzed children [2], adolescents [31, and adults [3, 4] demon-
strated that medical suppression of the parathyroid gland activ-
ity or parathyroidectorny was followed by normalization of the
glucose intolerance. In studies utilizing hyperglycemic clamps
[1—31, the absence of PTH or the normalization of its blood
levels resulted in a significant increase in the insulin response to
hyperglycemia without a change in the peripheral resistance to
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insulin. It was, therefore, concluded that excess blood levels of
PTH may interfere with the ability of the islets of Langerhans to
release adequate amounts of insulin [1—4] to overcome the
insulin resistant state usually present in uremia [5].
However, there is no direct evidence that the high blood
levels of PTH indeed impair insulin release. Further, in the
intact organism many other factors such as serum levels of
calcium, phosphorus, magnesium or potassium may modulate
the response of the pancreas to hyperglycemia. To further
elucidate the interaction between CRF, PTH and insulin re-
lease, we examined insulin secretion by islets of Langerhans
isolated from CRF rats with intact parathyroid glands, parathy-
roidectomized CRF rats, rats with normal renal function and a
state of hyperparathyroidism produced by prolonged adminis-
tration of PTH and control animals.
Methods
Sprague-Dawley rats weighing 320 to 375 g were studied.
They were fed normal rat chow diet (ICN Nutritional Biochem-
ical, Cleveland, Ohio, USA) throughout the study and allowed
to drink at libitum.
Two types of protocols were used. In the first protocol, the
rats were studied after 42 days of chronic renal failure in the
presence and absence of the parathyroid glands. Parathyroid-
ectomy (PTX) was performed by electrocautary, and the suc-
cess of the procedure was ascertained by a decrease in serum
levels of calcium of at least 2 mg/dl. The PTX rats were allowed
to freely drink water containing 5% of calcium gluconate. This
procedure is adequate to normalize plasma calcium in the PTX
rats. Seven days after PTX, the animals underwent a right
nephrectomy through a flank incision; four days later, a partial
left nephrectomy was performed. The nephrectomy procedure
was also done in rats with intact parathyroid glands. This
protocol, therefore, provided two groups of animals with CRF:
one with intact parathyroid glands (CRF-control) and the other
without parathyroid glands (CRF-PTX).
In the second protocol, normal rats received intraperitoneal
injection of 1-84 PTH (Sigma Chemical Company, St. Louis,
Missouri, USA) for 42 days. The hormone was dissolved in
normal saline and 50 g was injected in the morning and another
50 tg in the late afternoon. The control animals received sham
injections of the vehicle only.
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Serum
creatine
Insulin release pg/islet
Early Total
mg/dl (6 mm) (31 mm)
4 day
Control 0.53 0.03 249 36 3777 479
PTH-treated 0.56 0.04 279 27 3077 274
P NS NS NS
10 day
Control 0.51 0.06 201 87 3376 201
PTH-treated 0.47 0.02 287 98 4490 333
P NS NS <0.05
21 day
Control 0.52 0.04 275 62 3421 261
PTH-treated 0.40 0.05 208 35 3152 317
P NS NS NS
Control 0.43 .03 305 80 3581 329
CRF-control 1.28 .12 243 99 2345 499
P <0.01 NS <0.05
The animals were sacrificed by decapitation and the pancreas
was removed, dissected free of adipose tissue and lymph nodes.
Islets of Langerhans were isolated by the collagenase digestion
method of Lacy and Kostianovsky [6] and picked free of
exocrine tissue under a dissecting microscope. With every
study of CRF-control, CRF-PTX or PTH-treated rats a simul-
taneous study was performed in a normal animal when it was
technically feasible. The insulin release from islets of the
CRF-control and CRF-PTX were evaluated under static and
dynamic conditions and dynamic studies were performed on
islets from PTH-treated rats. Both the static and dynamic
studies were done according to methods previously reported [7,
8].
Briefly, in the static studies the islets were preincubated for a
period of 30 minutes at 37°C in a modified Krebs-Ringer
bicarbonate buffer (pH 7.4) containing 10 mr'vi HEPES and 0.5
mgldl bovine serum albumin (incubation media) and 2.8 mM
D-glucose. The islets were then matched for size by visual
inspection and groups of 10 islets were incubated in tubes
containing 1.0 ml of the incubation media and were studied with
the following secretagogues: a) 2.8 msi D-glucose; b) 16.7 mM
D-glucose; C) 100 LM isobutyl-l-methylxanthine (IBMX) and
16.7 mrvt D-glucose; and d) 10 LM forskolin and 16.7 mM
D-glucose. After 30 minutes of incubation in a shaker bath at
37°C, the supernatants were aspirated for determination of
insulin.
The dynamic studies were conducted in a four channel
perifusion apparatus utilizing previously described methods [81.
Twenty-five size-matched islets were placed in each of the four
conical chambers of 0.07 ml capacity and were perifused at a
rate of 0.8 mI/mm with the incubation media containing 2.8 mM
D-glucose at a temperature at 37°C and a gas mixture of 95% 02
and 5% CO2 being continuously bubbled into the perifusate.
After leaving the chambers, the perifusate was filtered through
8.0 rm pore size filter (Sartorius, Burlingame, California, USA)
and was collected. Each study was performed in duplicates.
After 39 minutes of preincubation, the collection of the effluent
was started and continued at a one minute interval for 41
minutes. The first six collections (6 minutes) represented the
basal level of insulin release during perifusion with 2.8 mtvi D-
glucose. Thereafter, the D-glucose concentration in the perifus-
ate was increased to 16.7 m and an additional 35 samples were
collected and insulin concentrations were determined ii various
samples of the effluent.
Calcium content of the pancreas was measured. About 0.5 to
1.0 g of pancreas was placed in tared porcelain crucibles and
weighed to 0.01 mg. All samples were dried at 105°C for 48
hours and then reweighed to determine water content. Samples
were then ashed for 12 hours in an oven with 700°C. The
samples were extracted in 0.75 N HNO3 for 24 hours and calcium
concentration was determined.
One hour intravenous glucose tolerance test was also done in
control, CRF-control and in CRF-PTX rats. The animals were
not fasted before the test. The jugular vein and carotid artery
were cannulated with PE 10 tubing under general anesthesia
with Ketamine-HCI 25 mg/kg (Bristol Laboratories, Syracuse,
New York, USA). The animals were allowed to recover from
the surgical procedure and were studied eight hours later in the
awake state. The rats received 0.5 g of D-glucose /kg body wt in
a bolus intravenous injection. A total of eight blood samples of
60 d were collected serially from the arterial line for the
measurement of glucose.
In the dynamic study of insulin release, the changes from
baseline with time were examined by calculating the area under
the curve for each study. Insulin release started to increase four
minutes after the change of the concentration of D-glucose in
the perifusate to 16.7 m. Therefore, the average values of
insulin release during the six minutes prior to the change in
glucose concentration and of the four minutes immediately
thereafter were used as a baseline level. The calculation of area
under the curve allowed us to estimate insulin release during the
Table 1. Early and total insulin release from pancreatic islets after
various periods of parathyroid hormone treatment and chronic renal
failure
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Fig. 1. The changes in plasma glucose concentration during intrac'e-
notis glucose tolerance test performed in 4 control rats (0), 5 CRF-
control rats (A), and 5 CRF-PTX animals (•). Each data point
represents the mean value and the bracket I SE.
Data are presented as mean SE of 4 studies.
Data of insulin release represent area under the curve SE.
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Fig. 2. Insulin release from pancreatic islet
during studies with static incubation in 13
normal rats (LI), 6 CRF-control rats (•) and6
CRF-PTX rats (). Each column represents
mean value and brackets I SE.
initial phase (5 mm between mm 4 to 9) and the total insulin
release (31 mm between mm 4 to 35).
The choice to perform the study after six weeks of PTH
administration or of CRF was based on results of experiments
carried out to determine the time relationship between the
duration of CRF or PTH treatment and insulin release from
pancreatic islets. We found that PTH treatment of 4, 10 and 21
days did not produce significant reduction in insulin release and
that the effects of 21 days of CRF were variable with only the
mean value of total insulin release being modestly significantly
(P < 0.05) lower than control. These data are shown in Table 1.
We therefore used the six weeks protocol where the effects on
insulin release was consistent and marked.
The measurement of calcium and magnesium was made with
Perkins Elmer atomic absorption spectrophotometer, model
503 (Perkin Elmer Corp., Norwalk, Connecticut, USA), those
of creatinine and phosphorus with Techincon autoanalyzer
(Techincon Instrument Inc., Tarrytown, New York, USA), and
those of glucose by glucose oxidase method utilizing Beckman
glucose analyzer II (Beckman Instruments, Inc., Fullerton,
California, USA). Insulin was determined by charcoal-coated
radioimmunoassay [9] using rat insulin as standard.
Statistical analysis was done with the Clinfo computer sys-
tem. The data are presented as mean SE. Changes from base
line in parameters with multiple measurements with time (glu-
cose tolerance and dynamic insulin release) were evaluated by
calculating area under the curve for each experiment utilizing
the trapezoidal rule. The areas under the curve as well as the
data from studies of static insulin release were analyzed by
one-way analysis of variance and compared with each other
using the Duncan multiple range test. Non-parametric analysis
was also done using Wilcox non-paired rank sum tests adjusted
for multiple comparison. The area under the curve for the
studies from control and PTH-treated rats were compared by
unpaired t-test.
Results
Intravenous glucose tolerance
Figure 1 depicts the changes in blood glucose during intrave-
nous glucose tolerance tests in control, CRF-control and CRF-
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Fig. 3. Dynamic insulin release from perifi4sed
pancreatic islets in 5 control rats (0), 5
CRF-control animal (A) and 5 CRF-PTX rats
40 (•). Each data point represents the mean
value and brackets I SE.
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Table 2. The biochemical data, insulin release during static studies and calcium content of pancreas in control, CRF-control an CRF-PTX rats
g
a. Control 356 6 055 004 9.2 0.2 6.9 0.3 1.7 0.07
N = 13
b. CRF-Control 343 5 1.90 0.08 9.3 0.4 6.4 0.94 2.7 0.3
N= 6
c. CRF-PTX 341 10 1.79 0.05 9.3 0.3 5.l 1.3 2.8 0.2
N— 6
P values
a vs. b NS <0.01 NS NS <0.05
a vs. c NS <0.01 NS NS <0.05
bvs.c NS NS NS NS NS
Abbreviations are: B, blood; Cr, creatinine; Ca, calcium; P, phosphorus; and Mg, magnesium. Data are presented as mean SE. N, increment of
IBMX-induced insulin release above 16.7 m glucose release. 2, increment of forskolin-induced insulin release above 16.7 mM gluocse release.
a The N for control is 6, for CRF control is 5 and for CRF-PTX is 6.
Table 2 continued next page.
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Fig. 4. Dynamic insulin release from
perifused pancreatic islets in 4 control
animal (0) and 6 PTH-treated rats (A).
40 Each data point represents the mean value
and brackets I SE.
PTX rats. The CRF-control animals demonstrated glucose
intolerance with the area under the curve being significantly
greater (P < 0.05) than in control rats. In contrast, glucose
tolerance was preserved in CRF-PTX rats with an area under
the curve not different from normal. Also blood glucose con-
centration at 45 and 60 minutes in CRF-coritrol rats was
significantly higher (P < 0.01) than corresponding values in
both normal and CRF-PTX rats.
Insulin release by pancreatic islets
The biochemical data, insulin release during static studies,
and calcium content of pancreas in control, CRF-control and
CRF-PTX rats are given in Table 2 and Figure 2. There were no
significant differences in the body weight and in the blood levels
of calcium and phosphorus among the three groups. The 5/6
nephrectomy resulted in a significant rise in the blood concen-
trations of creatinine and magnesium, but the latter two param-
eters were not significantly different among the two CRF groups
of animals. Calcium content of pancreas in CRF-control (11.2
0.7 g/kg dry wt) was significantly higher (P < 0.01) than in
normal (5.9 0.9 g/kg dry wt) or CRF-PTX rats (6.7 0.7 g/kg
dry wt). The calcium content of the latter animals were not
different from that of normal rats.
Insulin release induced by 16.7 m glucose during static
studies in CRF-control rats (54 4 pg/islet/mm) was signifi-
cantly lower (P < 0.01) than that in normal (88 4 pg/islet/mm)
or in CRF-PTX rats (90 10 pg/islet/mm), and insulin release in
the latter two groups were not significantly different. In pres-
ence of 16.7 mst glucose, both IBMX and forskolin significantly
(P < 0.01) stimulated insulin release in all three groups of
animals, but insulin release was significantly lower in CRF-
control than in normal and CRF-PTX. However, the increments
in insulin release induced by IBMX and forskolin were not
different among the three groups of animals.
Body
weight
B Cr B Ca
mg/dl
BP BMg
E
0U
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a
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Table 2. Continued
Insulin release pg/islet/mm
Forskolin
16.7 mrvi
glucose 2
Total
pancreatic
calciuma
g/kg dry
WI
2.8 mi
glucose
IBMX
16.7 msi 16.7 msi
glucose glucose 1
56± 0.7 86 9 148 14 62 12 131 12 45 7 5.9 0.9
3.3±0.5 56±5 93±6 37± 13 87±7 31±9 11.2±0.7
6.2 1.6 91 9 141 12 50 Ii 142 9 51 15 6.4 0.7
NS
NS
NS
<0.01 <0.01
NS NS
<0.01 <0.01
NS
NS
NS
0.01
NS
0.01
NS
NS
NS
<0.01
NS
<0.01
Insulin release during the dynamic studies is shown in Figure
3. It is evident that insulin release in CRF-control rats was
lower than in control or CRF-PTX animals. Early insulin
release (5 mm) calculated from area under the curve in CRF-
control rats (59 31 pg/islet) was significantly lower (P <0.01)
than in control (209 20 pg/islet) or CRF-PTX (187 26
pg/islet). Total insulin release (31 mm) was also significantly
lower (P < 0.01) in the CRF-control (1082 104 pg/islet) than
in control (3196 216 pg/islet) or in CRF-PTX (2856 356
pg/islet) rats. There were no significant differences between
early or total insulin release between control and CRF-PTX
rats.
The long term administration of 1-84 PTH to rats did not
cause significant changes in their weight (355 15 vs. 360 17
g), blood creatinine (0.7 0.09 vs. 0.6 0.10 mg/dl), blood
calcium (9.7 0.5 vs. 9.1 0.4 mg/dl) or blood magnesium
(1.87 0.4 vs. 1.71 0.1 mg/dl). The blood levels of phospho-
rus decreased modestly but significantly after PTH administra-
tion (6.7 0.3 vs. 7.6 0.3 mg/dl, P < 0.01). The calcium
content of the pancreas was significantly higher (P < 0.05) in
PTH-treated animals (7.4 0.6 g/kg dry wt) as compared to
control rats (5.9 0.9 g/kg dry wt).
Figure 4 depicts insulin release during dynamic studies in four
control rats and five PTH-treated rats. The initial insulin release
(5 mm) in the PTH-treated animals (140 12 pg/islet) was
significantly lower (P < 0.05) than in control (208 28 pg/islet).
Also total insulin release (31 mm) in PTH-treated rats (1979
82 pg/islet) was significantly lower (P < 0.01) than control rats
(3220 82 pg/islet).
Discussion
The results of the present study show that rats with six weeks
of CRF developed glucose intolerance, and this abnormality
was reversed by prior parathyroidectomy. These data are
similar to those reported in dogs [1] and in humans [2, 3] and
indicate that this rat model is suitable for the study of the effect
of CRF and PTH on insulin release.
Available data indicate that the state of glucose intolerance in
uremia is due to tissue resistance to insulin combined with
impaired ability of the (3-cell to release appropriate amounts of
insulin [5, 10] to overcome the peripheral resistance to the
hormone. Studies in humans [2, 3] and dogs [I] with chronic
renal failure have demonstrated that the state of secondary
hyperparathyroidism may impair insulin release from the pan-
creas. Indeed, correction of the hyperparathyroidism either by
medical suppression of the parathyroid gland activity or by
parathyroidectomy [1—41 was associated with an increase in
insulin release and correction of the carbohydrate intolerance
without a change in the peripheral resistance to insulin action.
Our data provide direct evidence that both the early and total
insulin release during stimulation with glucose, by islets from
rats with six weeks of CRF and intact parathyroid gland are
significantly impaired.
The blood levels of PTH were not measured in our animals
since the assay of PTH in the rat is not widely available and is
done in very few laboratories. However, current data indicate
that chronic renal failure in humans [11—13] and in dogs [1] is
associated with secondary hyperparathyroidism, and increased
activity of the parathyroid glands develops in rats within hours
after the induction of renal failure [14]. We can, therefore,
assume with high degree of confidence that our rats did have
secondary hyperparathyroidism.
Thus, the defect in insulin release by pancreatic islets ob-
tained from CRF-control rats appears to be due to the state of
secondary hyperparathyroidism of CRF. Two observations in
our study support this conclusion. First, both early and total
insulin release from islets of normocalcemic parathyroidectom-
ized rats with similar degree and duration of CRF were not
different from results obtained in normal rats. Second, insulin
release by isletsfrom rats with normal renal function and a state
of hyperparathyroidism produced by PTH administration for
six weeks was also significantly lower than insulin release from
islets of normal rats. Thus, insulin release is impaired in the
presence of hyperparathyroidism independent of the presence
or absence of CRF.
Available data indicate that stimulation of insulin release by
glucose is mediated by a rise in cytosolic calcium concentration
[15, 16]. It is believed that the increase in cytosolic calcium
concentration during the early phase of insulin release is
brought about by mobilization of calcium from intracellular
stores [16, 171 and this process may require energy [18]. On the
other hand, the rise in cytosolic calcium during the second
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phase of insulin release is due to an increase in calcium influx
into the /3-cells [15, 19, 201. Many other agents that act as
insulin secretogogues such as amino acids or acetylcholine also
increase cytosolic calcium [20, 21].
The mechanism through which excess PTH may blunt glu-
cose-induced insulin release is not as yet delineated. Several
possibilities should be considered. PTH has been shown to
acutely stimulate calcium influx into many cells [22—27], and
one would, therefore, expect that this hormone should stimu-
late rather than blunt insulin release. However, it is possible
that the effect of a chronic excess of PTH on the /3-cells is
different from an acute effect. A corollary to a different effect of
acute or chronic excess of PTH is found in observations in other
systems. Excess amount of the hormone acutely stimulates
chronotropic [28] and inotropic [29] properties of the heart cells
and enhances random motility of polymorphonuclear leuco-
cytes [30], but chronic exposure to excess PTH decreases or
stops the beating of heart cells [28], impairs the metabolism and
function of the heart [31] and reduces random motility of the
leukocytes [30]. The available data on insulin response to
hyperglycemia with primary hyperparathyroidism (a state of
chronic excess of PTH) do not help resolve these issues in that
these patients have hypercalcemia and/or hypophosphatemia,
both of which affects insulin release.
It is possible that the effects of changes in cytosolic calcium
of the /3-cells on insulin release depends on the magnitude of the
change and its duration. One may speculate that chronic
exposure to PTH may lead to sustained rise in cytosolic
calcium. Direct evidence for such a notion is not available, but
the calcium content of the pancreas was significantly increased
in the rats with hyperparathyroidism with and without CRF. If
this change in calcium content is equally distributed in the
pancreas, one may assume that calcium overloading of the islet
cells is present. Under such circumstances the capacity of
cellular oganelles to sequester calcium may approach saturation
and a new steady state with higher cytosolic calcium may
develop. This proposition requires confirmation with direct
measurements of cytosolic calcium.
Frankel, Atwater and Grodsky [32] have shown that higher
cytosolic calcium may activate potassium permeability, cause
repolarization of cell membrane and blunt insulin release. Also,
it is known that glucose-induced insulin release plateaus as
cytosolic calcium reaches a certain level [15]. If the /3-cells
during states of chronic hyperparathyroidism have high concen-
tration of calcium than normal, the critical level of cytosolic
calcium at which glucose-induced insulin secretion plateaus
would be reached earlier and insulin release would be blunted.
Chronic exposure to PTH in rats caused impairment in
energy production, shuttle and utilization by the myocardium
[31] and skeletal muscle [33]. It is, therefore, possible that a
similar effect on /3-cells of the pancreatic islet may reduce
energy availability necessary for calcium mobilization during
the initial phase of insulin release. Such an effect may blunt or
abolish the glucose-induced early insulin release and provide an
explanation for the observed reduction in insulin release in
CRF-control and PTH-treated rats.
It also appears that the reduction in insulin release in our rats
with excess PTH does not seem to be related to derangement in
the adenylate cyclase-cyclic AMP system. Indeed, an increase
in islet cyclic-AMP produced either by forskolin, which stimu-
lates adenylate cyclase activity [34], or by IBMX, which
inhibits phosphodiesterase activity [15], caused a similar incre-
ments in insulin secretion in the normal rats and in CRF animal
with and without excess PTH.
Finally, a potential role for an alteration of l,25(OH)2D
metabolism in the genesis of the reduced insulin release in
CRF-control and PTH-treated animals should be considered. It
has been demonstrated that the chick pancreas contains recep-
tors for l,25(OH)2D [35], and a vitamin D calcium-binding
protein is present in the pancreas and /3-cells of the chick and
rat [36—38]. Furthermore, Kadowaki and Norman [39] showed
that vitamin D deficiency in the rat is associated with a
reduction in glucose-induced insulin release from the pancreas,
and 1,25(OH)2D3 restored this abnormality. Thus, it appears
that this vitamin D metabolite may stimulate insulin release. In
our studies, the CRF-PTX rats should have lower levels of
1 ,25(OH)2D than CRF-control animals and the PTH-treated rats
should have elevated levels of this metabolite, since PTH
stimulates production of 1,25(OH)2D [40, 41]. However, the
insulin release was higher in PTX-CRF rats than CRF-control
rats and lower in PTH-treated animals than control ones. Thus,
these findings do not support the notion that the reduced insulin
release noted in our study is due to a deficiency in 1 ,25(OH)2D.
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